June 14, 2006Open Access
Dasatinib in Imatinib-Resistant Philadelphia Chromosome–Positive Leukemias
Key Points
Key points are not available for this paper at this time.
Abstract
Dasatinib induces hematologic and cytogenetic responses in patients with CML or Ph-positive ALL who cannot tolerate or are resistant to imatinib. (ClinicalTrials.gov number, NCT00064233 ClinicalTrials.gov.).
Connected Papers
Building similarity graph...
Analyzing shared references across papers
Discussion
Loading...
Authors
Moshe Talpaz
University of Verona
N
Neil P. Shah
Reckitt Benckiser (United Kingdom)
Hagop M. Kantarjian
The University of Texas MD Anderson Cancer Center
Journals
New England Journal of Medicine
Actions
Institutions
Howard Hughes Medical Institute
University of California, Los Angeles
The University of Texas MD Anderson Cancer Center
References and Citations
Connected Papers
Building similarity graph...
Analyzing shared references across papers
Discussion
Loading...